Antithrombin during veno-venous extracorporeal membrane oxygenation with heparin anticoagulation: A single-center cohort study
Perfusion · 2025
DOI: 10.1177/02676591241258048 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Perfusion, 2025. Verfasst von Bethany A Hileman und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Heparin, Anticoagulants, Antithrombins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Introduction
Antithrombin (AT) is a natural anticoagulant essential to enhancing the unfractionated heparin (UFH) anticoagulant effect. Its supplementation in the management of UFH-based anticoagulation during veno-venous extracorporeal membrane oxygenation (VV ECMO) has a strong pathophysiological rationale.
Methods
This is a single-center, retrospective cohort study of adult VV ECMO patients with anticoagulation maintained by UFH targeting an activated partial thromboplastin time (aPTT) of 40–50 s and AT activity >80%. We compare anticoagulation management and survival outcomes between AT subpopulations, defined by a threshold AT activity ≥80%. Linear and logistic regression analyses were used to evaluate the variation in AT activity and its association with ICU survival.
Results
In 244 patients enrolled from 2009 to 2022, anticoagulation was maintained by a median heparin dose of 11.4 IU/kg/h [IQR: 8.2–14.7] with a mean aPTT of 46.1 s (±7.3) and AT activity of 88.9% (±17.0). A lower mean aPTT, higher dose of UFH and shorter fraction of time without UFH were associated with higher AT activity ( p < .01). Higher AT activity showed a consistent association with ICU survival (for 10% increase of AT, odds ratio for ICU mortality: 0.95; 95% CI 0.93–0.97; p value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Department of Anesthesia and Intensive Care, Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione (IRCCS-ISMETT), Palermo, Italy.
- University of Pittsburgh Medical Center Italy, Palermo, Italy.
- Statistics and Data Management Services, Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione (IRCCS-ISMETT), Palermo, Italy.
- Cardiothoracic Surgery Department, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands.
- Department of Anesthesia and Critical Care, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
ORCID-Profile: Bethany A Hileman, Gennaro Martucci, Roberto Lorusso
Förderung
- Italian Ministry of Health
Zitieren
APA
Hileman, B. A., Martucci, G., Rizzitello, N., Occhipinti, G., Rossetti, M., Tuzzolino, F., Lorusso, R., Panigada, M., Tanaka, K., Arcadipane, A., & Panarello, G. (2025). Antithrombin during veno-venous extracorporeal membrane oxygenation with heparin anticoagulation: A single-center cohort study. Perfusion. https://doi.org/10.1177/02676591241258048
Vancouver
Hileman BA, Martucci G, Rizzitello N, Occhipinti G, Rossetti M, Tuzzolino F, et al. Antithrombin during veno-venous extracorporeal membrane oxygenation with heparin anticoagulation: A single-center cohort study. Perfusion. 2025. doi:10.1177/02676591241258048
BibTeX
@article{Hileman2025,
author = {Hileman, Bethany A and Martucci, Gennaro and Rizzitello, Nicolò and Occhipinti, Giovanna and Rossetti, Matteo and Tuzzolino, Fabio and Lorusso, Roberto and Panigada, Mauro and Tanaka, Kenichi and Arcadipane, Antonio and Panarello, Giovanna},
title = {Antithrombin during veno-venous extracorporeal membrane oxygenation with heparin anticoagulation: A single-center cohort study},
journal = {Perfusion},
year = {2025},
doi = {10.1177/02676591241258048}
}
EUVIMED